All Outputs (2)

Immunization with a synthetic consensus hepatitis C virus E2 glycoprotein ectodomain elicits virus-neutralizing antibodies (2018)
Journal Article
Tarr, A. W., Backx, M., Hamed, M. R., Urbanowicz, R. A., McClure, C. P., Brown, R. J., & Ball, J. K. (2018). Immunization with a synthetic consensus hepatitis C virus E2 glycoprotein ectodomain elicits virus-neutralizing antibodies. Antiviral Research, 160, 25-37. https://doi.org/10.1016/j.antiviral.2018.09.005

Global eradication of hepatitis C virus (HCV) infection will require an efficacious vaccine capable of eliciting protective immunity against genetically diverse HCV strains. Natural spontaneous resolution of HCV infection is associated with productio... Read More about Immunization with a synthetic consensus hepatitis C virus E2 glycoprotein ectodomain elicits virus-neutralizing antibodies.

Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus (2018)
Journal Article
Llibre, A., Shimakawa, Y., Mottez, E., Ainsworth, S., Buivan, T., Firth, R., …Duffy, D. (2018). Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus. Gut, 67(11), 2017-2024. https://doi.org/10.1136/gutjnl-2017-315783

Objective: Recently approved direct acting antivirals provide transformative therapies for chronic hepatitis C virus (HCV) infection. The major clinical challenge remains to identify the undiagnosed patients worldwide, many of whom live in low-income... Read More about Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus.